TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02310919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose hCG plus FSH co-trigger
Description: Low dose hCG (1,500 IU) plus FSH (450 IU) co-trigger
Study: NCT00748592

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects in this arm will be administered 3 capsules of placebo 30 minutes before bedtime for two consecutive nights in the sleep lab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0200390
Description: Subjects in this arm will be administered 3 capsules totaling 5 milligrams 30 minutes before bedtime for two consecutive nights in the sleep lab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0200390
Description: Subjects in this arm will be administered 3 capsules totaling 15 milligrams 30 minutes before bedtime for two consecutive nights in the sleep lab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0200390
Description: Subjects in this arm will be administered 3 capsules totaling 30 milligrams 30 minutes before bedtime for two consecutive nights in the sleep lab.
Study: NCT03051386

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VEE Vaccine
Description: 0.5 mL of VEE vaccine administered subcutaneously in the upper outer aspect of the triceps region.
Study: NCT03329053

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The EAPC Exercise Prescription (EXPERT) Tool
Description: During the 30-minute long consultation subjects will receive standard, usual-cardio-care lifestyle, hypertension and cardiovascular instructions, except recommendations for physical activities. This domain will be consulted exclusively through the digital training and decision support tool.~The EXPERT tool is an interactive digital training and decision support system for optimized exercise prescription in cardiovascular disease patients. The EXPERT tool was designed to provide optimized exercise prescription based on detailed overview of patient´s diagnosis, prognostics, complications and medication.
Study: NCT03727932

Intervention type: DEVICE
Group type: OTHER
Intervention: VioOne HIV Profile Supplemental Assay
Description: The VioOne™ HIV Profile™ Supplemental Assay is an enzyme-linked immunosorbent assay (ELISA) for confirmation and differentiation of individual antibodies directed to various gene products of Human Immunodeficiency Virus Type 1 (HIV-1 Group M \& Group O) and Type 2 (HIV-2) in human serum or plasma. The HIV Profile™ is intended as an aid in the diagnosis of infection with HIV-1 and/or HIV-2.
Study: NCT02602119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTL38
Description: Infusion of OTL38 prior to surgery
Study: NCT03329053

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Cardio-Care Lifestyle Counselling
Description: During the 30-minute long consultation subjects will receive standard, usual-cardio-care lifestyle, hypertension and cardiovascular instructions also in the domain of recommendations for physical activities. The exercise prescription process during consultation will be constructed in accordance with published guidelines and recommendations for secondary prevention of cardiovascular diseases.
Study: NCT00991458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine 0.010% eye drops
Description: Cyclosporine 0.010% eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine 0.005% eye drops
Description: Cyclosporine 0.005% eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
Study: NCT02310919

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard dose of hCG
Description: Standard dose of hCG (10,000 or 5,000 IU) trigger
Study: NCT03821558

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: Patients to be randomized to the 'interval training group' or 'continuous training group' will undergo exercise training sessions with different intensity levels.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: Patients to be randomized to the 'interval training group' or 'continuous training group' will undergo exercise training sessions with different intensity levels.
Study: NCT02381418

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent influenza subunit vaccine Influvac
Description: 3x 15mcg HA per 0.5 ml,trivalent one injection at Day 1
Study: NCT00991458

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Vehicle for Cyclosporine)
Description: Placebo eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
Study: NCT03336216

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cabiralizumab
Description: specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cabiralizumab
Description: specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cabiralizumab
Description: specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: specified does on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: specified does on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Onivyde
Description: specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: specified dose on specified days
Study: NCT02933333

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a hematopoietic CSFs that decrease the duration and severity of neutropenia for patients receiving chemotherapy. GM-CSF is a stimulator of the growth and differentiation of hematopoietic progenitor cells committed to neutrophils, monocytes or eosinophils.
Study: NCT02504528

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: house dust mites
Description: house dust mites(two-fold increasing concentration of house dust mite (HDM) extract, dilutions prepared starting from 1:8, 1:16, 1:32, 1:64, 1:128, 1: 256, 1:512, 1:1024,......)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: house dust mites
Description: house dust mites(two-fold increasing concentration of house dust mite (HDM) extract, dilutions prepared starting from 1:8, 1:16, 1:32, 1:64, 1:128, 1: 256, 1:512, 1:1024,......)
Study: NCT01950221

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: POMx
Description: POMx is a 1,000 milligram capsule of natural pomegranate polyphenol extract.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04659642

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine Injection [Precedex]
Description: the drug is given 15 minutes before the estimated end of surgery
Study: NCT02933333

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Granulocyte colony-stimulating factor (G-CSF) is a hematopoietic CSFs that decrease the duration and severity of neutropenia for patients receiving chemotherapy. G-CSF is a relatively specific stimulator of the growth and differentiation of hematopoietic progenitor cells committed to the neutrophil lineage.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GM-CSF and G-CSF
Description: Granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) are hematopoietic CSFs that decrease the duration and severity of neutropenia for patients receiving chemotherapy. GM-CSF and G-CSF share a number of biologic activities, GM-CSF seems to be more potent against fungi.
Study: NCT03336216

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: specified dose on specified days
Study: NCT01769196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simtuzumab
Description: 125 mg/mL single-dose vials administered subcutaneously once a week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Simtuzumab placebo
Description: Simtuzumab placebo single-dose vials administered subcutaneously once a week
Study: NCT00438165

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: home visitation
Description: Home visitation by nurses from midway through pregnancy until child age 12
Study: NCT05993910

Intervention type: OTHER
Intervention: Hyperthermie Register
Description: * die Höhe der Temperatur im Zielgebiet (42,5 bis 43 °C),~* die Dauer der Anwendung und~* die simultane Therapie mit Chemo- und/oder Strahlentherapie
Study: NCT03336216

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: specified dose on specified days
Study: NCT04659642

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl Citrate Injection
Description: the drug is given 15 minutes before the estimated end of surgery

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine and fentanyl
Description: the combination of the two drugs with the same used doses is given 15 minutes before the estimated end of surgery
Study: NCT03336216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: specified dose on specified day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan Hydrochloride
Description: Specified dose on specified days
Study: NCT02719886

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Estimation of fetal weight by ultrasound

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Estimation of fetal weight by ultrasound
Study: NCT03385317

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Study: NCT01436240

Intervention type: BEHAVIORAL
Intervention: questionnaire administration followed by cognitive interviews
Description: Each cognitive interviewing procedure will include two parts. Participants will first be asked to independently complete a series of PRO-CTCAE symptom items in a Patient Questionnaire. Following completion by the participant of the Patient Questionnaire containing PRO-CTCAE items, the bilingual interviewer will query participants regarding item comprehension, relevance, inclusiveness, cultural appropriateness, and cognitive processes used to generate responses, via a semi-scripted cognitive debriefing interview developed to assure consistency across interviews.
Study: NCT01037686

Intervention type: RADIATION
Group type: OTHER
Intervention: Injection of 15mCi of Tc-ECD and scanning by SPECT camera
Description: All subjects (PD patients with or without DBS and healthy controls) will be injected with 15mCi of Tc-ECD and afterwards will be scanned by an Irix SPECT camera.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Semantic verbal fluency task performance
Description: All Subjects (PD patients with or without DBS and healthy controls) before one of the two scans will perform the semantic verbal fluency task during the Tc-ECD uptake for 9 minutes. Before the other scan subjects will be at rest.

Intervention type: DEVICE
Group type: OTHER
Intervention: Turning off the stimulator
Description: For PD patients treated with DBS, the neurologist will turn off the stimulator after the injection of Tc-ECD for ten minutes and then turn it back on.
Study: NCT04628312

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Static footprint
Description: The static footprint will measure the plantar pressures and surface area of the back of the foot, midfoot and forefoot. Subjects were instructed to stand barefoot on the force platform, participants were instructed to remain in a relaxed standing posture with feet shoulder-width apart and positioned 30 degrees from the midline.
Study: NCT01732770

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Denosumab 60 mg administered by subcutaneous injection once every 6 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic Acid
Description: Zoledronic acid 5 mg administered by intravenous infusion once a year

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Denosumab
Description: Administered by subcutaneous injection once every 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Zoledronic Acid
Description: Administered by intravenous infusion once a year
Study: NCT04327024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verinurad
Description: The treatment will be titrated in 3 steps for target low dose (3 mg), intermediate dose (7.5 mg) and high dose (12mg) of verinurad.~Drug: Allopurinol The treatment will be titrated in 3 steps. Low dose (100mg), intermediate (200mg) and high dose (300mg) of allopurinol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Study treatments will be titrated in 3 steps: Low dose (100mg), intermediate (200mg) and high dose (300mg) of allopurinol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Study treatments will be titrated in 3 steps: Low dose (100mg), intermediate (200mg) and high dose (300mg) of allopurinol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for verinurad
Description: Matching Capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for allopurinol
Description: Matching tablet
Study: NCT00791089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOVAZA Omega 3-acid ethyl esters
Description: Treatment with omega-3 fatty acids (4g/day) for 4 weeks before and 3 months after radiofrequency catheter ablation for AF.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOVAZA
Description: (EPA+DHA 4 gram/day) for 4 weeks before and 3 months after the ablation procedure.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Control group will receive placebo before \& after ablation.
Study: NCT04406025

Intervention type: PROCEDURE
Intervention: participation in Regional Anesthesia Seminar
Description: this group of anesthesiologists attended the Regional Anesthesia Seminar

Intervention type: PROCEDURE
Intervention: no participation in Regional Anesthesia Seminar
Description: this group of anesthesiologists did not attend the Regional Anesthesia Seminar
Study: NCT03986528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kanglaite Injection+Chemotherapy
Description: Patients will receive investigator's choice of paclitaxel (135mg/m2 by IV infusion on Day 1 of each 21-28 day cycle) or pemetrexed (500mg/m2 by IV infusion on Day 1 of each 21-28 day cycle) or gemcitabine(1000mg/m2 by IV infusion on Days 1,8 of each 21-28 day cycle) PLUS cisplatin (75mg/m2 by IV infusion on Days 1 to 3 of each 21-28 day cycle) or carboplatin (AUC 6 by IV infusion on Days 1 of each 21-28 day cycle) according pathologic types. Patients with CR, PR, or SD after 4-6 cycles of platinum-based double chemotherapy regimens will receive non-platinum single-agent chemotherapy. The patients will also receive Kanglaite injection 200ml by IV infusion per day continuously for 14 days, commencing on the first day of chemotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Patients will receive investigator's choice of paclitaxel (135mg/m2 by IV infusion on Day 1 of each 21-28 day cycle) or pemetrexed (500mg/m2 by IV infusion on Day 1 of each 21-28 day cycle) or gemcitabine(1000mg/m2 by IV infusion on Days 1,8 of each 21-28 day cycle) PLUS cisplatin (75mg/m2 by IV infusion on Days 1 to 3 of each 21-28 day cycle) or carboplatin (AUC 6 by IV infusion on Days 1 of each 21-28 day cycle) according pathologic types. Patients with CR, PR, or SD after 4-6 cycles of platinum-based double chemotherapy regimens will receive non-platinum single-agent chemotherapy.
Study: NCT00321464

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Q4W 120 mg denosumab SC injection and 4 mg zoledronic acid (Zometa) placebo IV over a minimum of 15 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic Acid
Description: Q4W 4 mg zoledronic acid IV over minimum 15 minutes and 120 mg denosumab placebo SC
Study: NCT01318837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: solifenacin
Description: oral
Study: NCT00610311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 60 mg/kg day x 2 days intravenous in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg day x 2 days over 1 hour

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: 25 mg/m\^2 day intravenous piggy back over 30 minutes for 5 days
Study: NCT01581463

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liothyronine, Sodium
Description: Single 100-microgram (2 X 50 microgram) dose.
Study: NCT02166190

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency Ablation using EndoHPB Probe
Description: Radiofrequency Ablation using EndoHPB Probe

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stenting only
Description: Stenting only
Study: NCT01457599

Intervention type: PROCEDURE
Intervention: Computertomography-guided marking of colorectal liver metastases
Description: Computertomography-guided marking of colorectal liver metastases
Study: NCT03033017

Intervention type: OTHER
Intervention: Blood Testing
Study: NCT02859649

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: neuropsychological test
Description: neuropsychological test
Study: NCT01321788

Intervention type: DRUG
Intervention: TINZAPARIN
Description: Eligible women following cesarean section will randomly receive once-daily injections of study drug (4,500 IU tinzaparin sodium within 12 to 24 hours postpartum and continued for two (2) weeks postpartum.

Intervention type: DRUG
Intervention: PLACEBO
Description: Eligible women following cesarean section will receive a once-daily injections of placebo within 12 to 24 hours postpartum and continued for two (2) weeks postpartum.
Study: NCT01102413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monofer
Description: Infusion or injections

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron Sulphate
Description: Oral intake
Study: NCT03219697

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parenting education program
Description: 8-week parent/caregiver education program, followed by two booster sessions. You and/or your partner will attend weekly parenting sessions which will take place either at the office of your child's primary care provider or virtually. Our Toronto Public Health Nurse, will arrange 2 home visits/virtual visits with you and your family along with 4 coaching calls during the 6 months. This first home visit will include learning more about your routines at home, and what is available in your neighbourhood. The home visits will focus on helping to apply the messages and skills from the group sessions for your family, and making connections in your community that you find helpful such as recreational or nutrition programs or other supports for your family.
Study: NCT00816699

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: preprint preoperative anesthetic risk information
Description: preprint preoperative anesthetic risk information

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: preprint preoperative anesthetic risk information
Description: preprint preoperative anesthetic risk information
Study: NCT01290848

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Take TIME Health Campaign
Description: 1. Provision of free, family-based events, at least twice per month, that offer opportunities for physical activity and/or healthy eating in a safe, tobacco-free environment.~2. Information dissemination, via project web site, media and other formats, on how to achieve a healthier lifestyle with the already hectic family schedules.~3. Adoption of guidelines by community organizations and the Township of Uxbridge that will reduce tobacco exposure, increase safety and promote physical activity and healthy eating for young children.
Study: NCT00610311

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: 720,000 IU/kg intravenously over 15 minutes every 8 hours (+/- 1 hour) for up to 5 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALVAC gp100 Vaccine
Description: 0.5 ml containing a target dose of 10\^7 CCID50 (with a range of approximately 10\^6,4 to 10\^7,9/mL) of the gp100 ALVAC virus subcutaneously in each extremity (total of 4 x 10\^7 CCID50/2mL)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-gp100:154-162 Tcell receptor (TCR) peripheral blood lymphocyte (PBL)
Description: 3 x 10\^11 anti-gp100:154-162 TCR engineered PBL by intravenous infusion. A minimum of approximately 5 x 10\^8 cells will be given.